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NAD kinase (NADK, EC 2.7.1.23) is the sole NADP
+
-biosynthetic enzyme that 2 
catalyzes phosphorylation of NAD
+
 to yield NADP
+
 using ATP as a phosphoryl 3 
donor, and thus, plays a vital role in the cell and represents a potentially powerful 4 
antimicrobial drug target. Although methods for expression and purification of 5 
human NADK have been previously established (F. Lerner, M. Niere, A. Ludwig, M. 6 
Ziegler, Biochem. Biophys. Res. Commun. 288 (2001) 69-74), the purification 7 
procedure could be significantly improved. In this study, we improved the method 8 
for expression and purification of human NADK in Escherichia coli and obtained a 9 
purified homogeneous enzyme only through heat treatment and single column 10 
chromatography. Using the purified human NADK, we revealed a sigmoidal kinetic 11 
behavior toward ATP and the inhibitory effects of NADPH and NADH, but not of 12 
NADP
+
, on the catalytic activity of the enzyme. These inhibitory effects provide 13 
insight into the regulation of intracellular NADPH synthesis. Furthermore, these 14 
attributes may provide a clue to design a novel drug against Mycobacterium 15 
tuberculosis in which this bacterial NADK is potently inhibited by NADP
+
.  16 
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 are cofactors involved in oxidative–reductive reactions [1, 2]. 3 
The function of NAD(H) (NAD
+
 and NADH) is distinguishable from that of 4 
NADP(H) (NADP
+
 and NADPH). NAD(H) mainly functions in catabolic reactions, 5 
while NADP(H) is involved in anabolic reactions and defense against oxidative 6 
stress [3]. NAD
+
 also functions as a substrate for mono- and poly-ADP-ribosylation 7 
and is involved in cyclic ADP-ribose synthesis [2] and histone deacetylation [4]. 8 
NADP
+
 functions as a substrate in the synthesis of nicotinic acid adenine 9 
dinucleotide phosphate, which is a potent intracellular Ca
2+
-mobilizing messenger [1, 10 
2, 5].  11 
NAD kinase (NADK, EC 2.7.1.23) is the sole NADP
+
-biosynthetic enzyme that 12 
catalyzes phosphorylation of NAD
+
 to yield NADP
+
 using ATP as a phosphoryl 13 
donor [1], and thus, plays a vital role in the cell. Accordingly, NADK has been found 14 
to be essential for many microbes, including Mycobacterium tuberculosis [6], 15 
Bacillus subtilis [7], Staphylococcus aureus [8], Haemophilus influenzae [8], 16 
Escherichia coli [8, 9], Streptococcus pneumoniae [8], Salmonella enterica [9, 10], 17 
and Saccharomyces cerevisiae [11, 12], thus representing a potentially powerful 18 
antimicrobial drug target [13, 14]. Several bacterial recombinant NADKs have been 19 
characterized in detail, including those from E. coli [15], B. subtilis [16], and M. 20 
tuberculosis [17, 18]. Moreover, tertiary structures of NADKs from the pathogenic 21 
bacteria M. tuberculosis [19, 20] and Listeria monocytogenes [21] have been 22 
published. However, the tertiary structure of human NADK has not yet been 23 
reported.  24 
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Lerner et al. [22] established methods for expression and purification of human 1 
NADK and determined some properties of this enzyme [22]. Although they provided 2 
a detailed purification procedure, the procedure still has needed several steps such as 3 
heat treatment followed by DEAE column chromatography and 4 
nickel–nitrilotriacetic acid column chromatography. Thus, an improvement in the 5 
methods for expression and purification of human NADK would facilitate further 6 
study of this vital enzyme. Further determination of the structure and catalytic 7 
properties of human NADK would provide a good foundation for designing a novel 8 
antimicrobial drug [13]. 9 
In this article, we describe improved methods to express and purify human 10 
NADK, thus enabling to obtain larger amounts of the purified homogeneous enzyme. 11 
In addition, we reveal some kinetic properties of human NADK that will provide 12 
insight into the regulation of intracellular NADPH synthesis and possibly a clue to 13 
design a novel antimicrobial drug. 14 
 15 
Materials and methods 16 
 17 
Strains and plasmids 18 
 19 
As a host for plasmid amplification, E. coli DH5 and JM109 were routinely 20 
cultured at 37 °C in Luria-Bertani (LB) medium containing 1% tryptone, 0.5% yeast 21 
extract, 1% NaCl, and ampicillin (100 µg/ml) (pH 7.2). E. coli M15 (pREP4) and 22 
SG13009 (pREP4) were purchased from Qiagen (Hilden, Germany), and E. coli 23 
Rosetta-gami, Rosetta-gami(DE3), Rosetta-gami(DE3)pLysS, Rosetta-gami 2(DE3), 24 
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and Rosetta-gami B(DE3) were obtained from Novagen (Darmstadt, Germany). The 1 
culture conditions for these E. coli strains are described below. 2 
Human NADK cDNA was amplified by PCR using human leukocyte cDNA 3 
(QUICK-Clone cDNA, Clontech, shiga, Japan) as a template and primers 4 
[HsNADKBamHI-f, CGGGATCCATGGAAATGGAACAAGAAAAAATGAC (the 5 
BamHI site is underlined) and HsNADK-C(NoRe)-r, 6 
CTAGCCCTCCTCCTCCTCCTC], and was inserted into the HincII site of pUC18, 7 
resulting in pMK1966. Human NADK cDNA obtained by digestion of pMK1966 8 
with BamHI was inserted into the BamHI site of pQE-30 (Qiagen), yielding 9 
pMK2071. The primary structure encoded by the cloned cDNA was identical to that 10 
of the cDNA sequence (with Phe (Glu)9 Gly as C-terminus) deposited in the NCBI 11 
database (accession no. NP_001185922), except that the former contains one 12 
additional Glu residue at its C-terminus, i.e., it has Phe (Glu)10 Gly.  13 
A DNA fragment encoding for an N-terminal sequence consisting of 87 amino 14 
acid residues of human NADK was excised from the full-length cDNA clone 15 





. This deletion was generated by inverse 17 
PCR using primers (5′-CACATTCAGGACCCCGCGAG-3′ and 5′- 18 
CATATGTCCGTGATGGTGATGGTG-3′). The recombinant proteins encoded by 19 
pMK2071 and pMK2784 contained a His-tag (MRGSHHHHHHGS) at their 20 
N-terminal sites.  21 
To express human NADK cDNA, pMK2071 was introduced into E. coli M15 22 
(pREP4), SG13009 (pREP4), and Rosetta-gami, yielding MK2105, MK2106, and 23 
MK2107, respectively. pMK2784 was introduced into E. coli Rosetta-gami(DE3), 24 
6 
 
Rosetta-gami(DE3)pLysS, Rosetta-gami 2(DE3), and Rosetta-gami B(DE3), 1 




The cells were precultured overnight in LB media supplemented with 100 µg/ml 6 
ampicillin and 25 µg/ml kanamycin (MK2105 and MK2106) or with 100 µg/ml 7 
ampicillin and 34 µg/ml chloramphenicol (MK2107, MK2801, MK2802, MK2803, 8 
and MK2804). The cells were collected, inoculated in LB media supplemented with 9 
the same antibiotics, and aerobically cultured at 37 °C until A600 reached 0.50–1.0. 10 
Isopropyl--D-thiogalactopyranoside was then added to obtain a final concentration 11 
of 0.025 or 1.0 mM in order to induce expression of human NADK. Cell cultivation 12 
was continued further at 16 or 37 °C under aerobic conditions for 4, 8, 12, or 24 h. To 13 
purify human NADK, MK2107 and MK2802 were cultivated at 37 °C for 8 h 14 
(MK2107) or 12 h (MK2802) after the addition of 15 
isopropyl--D-thiogalactopyranoside at 1.0 mM. To prepare the crude extract, cells 16 
were collected by centrifugation, suspended in 10 mM Tris-HCl (pH8.0), and 17 
sonicated to yield cell lysate. Before and after sonication, phenylmethylsulfonyl 18 
fluoride was added to obtain a final concentration of 1.0 mM. After centrifugation of 19 









NADK activity of human NADK was assayed at 37 °C by the modified 3 
continuous method [23]. Briefly, NADPH formation was continuously measured at 4 
A340 in a reaction mixture (1.0 ml) containing 5.0 mM NAD
+
, 5.0 mM ATP, 5.0 mM 5 
glucose-6-phosphate, 0.5 U glucose-6-phosphate dehydrogenase (Sigma, St. Louis, 6 
MD, USA), 5.0 mM MgCl2, and 100 mM Tris-HCl (pH 8.0). In the purified enzyme 7 
assay, MgCl2 was used at 10 mM. Enzyme activity was assayed by a stop method 8 
[23] to determine inhibitory effects and optimum pH and temperature conditions. 9 
Briefly, the amount of NADP
+
 formed was enzymatically determined using 0.5 U 10 
glucose-6-phosphate dehydrogenase after the reaction was terminated by immersing 11 
the test tube in boiling water for 5 min. Glucose-6-phosphate and 12 
glucose-6-phosphate dehydrogenase were removed from the reaction mixture as 13 
described above. When the inhibitory effects of NADP(H) and NADH were 14 
investigated, control reactions without human NADK were simultaneously 15 
performed in every assay.  16 
NADH kinase activity was assayed in a reaction mixture (1.0 ml) containing 2.0 17 
mM NADH, 5.0 mM ATP, 10.0 mM MgCl2, and 100 mM Tris-HCl (pH 8.0) [23]. 18 
One unit of enzyme activity was defined as 1.0 µmol NADP(H) produced in 1 min at 19 
37 °C, and specific activity was expressed in U/mg protein. Protein concentrations of 20 
the crude extract and purified human NADK from MK2107 were determined by the 21 
Bradford method [24]. Protein concentrations of purified human NADK from 22 
MK2802 were determined using the extinction coefficient (33,920) at A280. The 23 
extinction coefficients were calculated using the ProtParam tool on the ExPASy 24 
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Centrifugation was performed at 20,000 g and 4 °C for 10 min. Human NADK 5 
was expressed from MK2107 cells cultured in 2 l LB (0.5 l per 2 l Erlenmeyer flask) 6 
as described above and treated as described [22]. This was followed by Mono Q 7 
chromatography. The partially purified human NADK was applied to Mono Q 5/50 8 
GL (0.5  5.0 cm) (GE Healthcare, Buckinghamshire, England) equilibrated with 9 
buffer A (20 mM Tris-HCl (pH 8.5), 0.10 mM NAD
+
, 0.50 mM dithiothreitol, 1.0 10 
mM ethylenediaminetetraacetic acid, and 0.10 mM pepstatin A). After washing the 11 
column with 18 ml buffer A, elution was performed with a linear gradient of NaCl 12 
from 0 to 1.0 M in buffer A. Fructions that were obtained by an elution at 370–470 13 
mM NaCl were combined, dialyzed against buffer A, and used as purified human 14 
NADK. 15 
Human NADK was purified from MK2802 as stated below. Crude extract was 16 
prepared from MK2802 cells cultured in 13.5 l LB (1.5 l per 2 l Sakaguchi flask) and 17 
was treated as described above. Samples were heated at 60 °C for 5 min and 18 
centrifuged. The supernatant was applied to a TALON column (1.5  22 cm) 19 
(Clontech) equilibrated with 10 mM Tris-HCl (pH8.0). The column was washed with 20 
2 l of 10 mM Tris-HCl (pH8.0) containing 0.30 M NaCl. Human NADK was eluted 21 
with 10 mM Tris-HCl (pH8.0) containing 0.30 M NaCl and 150 mM imidazole. 22 
Fractions were combined, dialyzed against 10 mM Tris-HCl (pH 8.0), and used as 23 
purified human NADK. Alternatively, the crude extract prepared from MK2802 cells 24 
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was treated as mentioned above and was directly applied to the TALON column 1 
without heat treatment. The column was washed with 2 l of 10 mM Tris-HCl (pH8.0) 2 
containing 0.30 M NaCl and 30 mM imidazole, and eluted as above. 3 
 4 
Other analytical methods 5 
 6 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 7 
performed using a 12.5% polyacrylamide gel [25]. Proteins in the gel were visualized 8 
with Coomassie brilliant blue R-250. The molecular mass of the enzyme was 9 
estimated by gel filtration chromatography as described [26]; however, 10 mM 10 
Tris-HCl (pH 8.0) containing 0.15 M NaCl was used as an elution buffer. For the 11 
N-terminal amino acid sequence, purified and unpurified enzymes were transferred 12 
to a polyvinylidene difluoride membrane and analyzed using a Procise 492 protein 13 
sequencing system (Applied Biosystems Division of Perkin-Elmer, Foster City, CA, 14 
USA).  15 
 16 
Results and discussion 17 
 18 
Improved methods to express and purify human NADK 19 
 20 
According to the method described by Lerner et al. [22], we expressed the 21 
full-length human NADK cDNA cloned into pQE-30 (pMK2071) using an E. coli 22 
M15 (pREP4) host cell and obtained 0.23 U/mg NADK activity in the crude extract 23 
(Table 1). To improve expression, effects of the host cells (E. coli SG13009 (pREP4) 24 
10 
 
or Rosetta-gami), concentrations of isopropyl--D-thiogalactopyranoside (0.025 or 1 
1.0 mM), and induction conditions (16 or 37 °C and 4, 8, 12, or 24 h) were examined. 2 
Maximum expression (1.02 U/mg) was obtained in the crude extract when 3 
expression was induced at 37 °C for 8 h with 1.0 mM 4 
isopropyl--D-thiogalactopyranoside using E. coli Rosetta-gami (Table 1). The 5 
expressed human NADK was treated according to the purification procedure 6 
described by Lerner et al. [22]. However, this procedure yielded an unpurified 7 
enzyme. The unpurified enzyme was further purified by Mono Q chromatography as 8 
described in Materials and methods. The purified enzyme (0.39 mg; 7.21 U/mg) was 9 
obtained from a 2 l culture. SDS-PAGE analysis showed that the subunit molecular 10 
mass of the purified enzyme was 43 kDa, which was smaller than that predicted (49 11 
kDa) from the primary structure (data not shown). Analysis of the N-terminal amino 12 
acid sequence of the purified enzyme confirmed that the enzyme lacked the 13 
N-terminal sequences consisting of 60, 63, and 74 amino acid residues of human 14 
NADK, indicating the heterogeneity of the purified enzyme.  15 
To circumvent this problem, the DNA region that encoded the N-terminal 16 
sequence consisting of 87 amino acid residues of human NADK was excised from 17 
the full-length human NADK cDNA as described in Materials and methods. The 18 
deleted human NADK was expressed in E. coli Rosetta-gami(DE3), and it showed a 19 
specific activity of 0.79 U/mg (Table 1). Further optimization of the expression 20 
condition revealed that induction at 37 °C for 8–12 h in the presence of 1.0 mM 21 
isopropyl--D-thiogalactopyranoside using E. coli Rosetta-gami(DE3)pLysS as a 22 
host cell gave the maximum specific activity (4.29 U/mg). This activity was 23 
improved by approximately 18.7-fold compared with our initial attempt (0.23 U/mg; 24 
11 
 
Table 1). Moreover, we found that the heat treatment, followed by TALON column 1 
chromatography was sufficient to obtain the purified enzyme (9.34 U/mg, Fig. 1a). 2 
The subunit molecular mass of the purified enzyme (43 kDa) was in good agreement 3 
with the predicted mass (41 kDa). The N-terminal amino acid sequence of the 4 
enzyme was RGSHH, which corresponded to that of the His-tag, confirming the 5 
homogeneity of the purified enzyme. In all purification experiments, the purified 6 
enzyme (15 mg) was routinely obtained from a 13.5 l culture. Thus, we improved the 7 
methods for expression and purification of human NADK (Table 2, Fig. 1a).  8 
We also found that the enzyme could be purified only through TALON column 9 
chromatography without heat treatment (Fig. 1b). However, the purified NADK 10 
without heat treatment yielded three peaks (representing 210, 400, and 650 kDa) on 11 
gel filtration chromatography; each peak showed NADK activity. NADK in each 12 
peak was not divided into three peaks on repeated gel filtration chromatography (data 13 
not shown), thus indicating the heterogeneity in the quaternary structure of this 14 
human NADK. In contrast, the purified enzyme obtained by heat treatment, which 15 
was followed by TALON column chromatography (Fig. 1a), yielded a single peak 16 
representing 172 kDa (data not shown). Thus, the procedure using heat treatment was 17 
considered preferable for enzyme purification, and the properties of human NADK 18 
purified by this procedure were determined. 19 
 20 
Properties of human NADK 21 
 22 
Although the properties of purified human NADK were similar to those reported 23 
[22] (Table 3), we found that human NADK exhibits sigmoidal kinetic behavior 24 
12 
 
toward ATP, while saturation curve toward NAD
+
 (Fig. 2). The sigmoidal kinetic 1 
behavior was emphasized by a Hanes–Woolf plot (Fig. 2b). The sigmoidal kinetic 2 
behavior toward ATP was also observed in NADKs from B. subtilis [16] and M. 3 
tuberculosis [18]. With regard to NAD
+
, M. tuberculosis NADK shows sigmoidal 4 
kinetic behavior [18], whereas B. subtilis NADK exhibits a saturation curve [16].  5 
NADH-phosphorylating (NADH kinase) activity of recombinant human NADK 6 
was qualitatively, but not quantitatively, demonstrated by Pollak et al. [27]. We 7 
showed that human NADK exhibited NADH kinase activity (0.6 U/mg), accounting 8 
for only 5.0% of NADK activity (11.9 U/mg) determined in the presence of 2.0 mM 9 
NAD
+
. Some bacterial NADKs, such as those from M. tuberculosis, utilize inorganic 10 
polyphosphate as a phosphoryl donor [17, 18]. Inorganic polyphosphate is a polymer 11 
of inorganic orthophosphate residues linked by a high-energy phosphoanhydride 12 
bond [28], and is available as metaphosphate, hexametaphosphate, and 13 
tetrapolyphosphate. The relative activities of purified human NADK in the presence 14 
of 1 mg/ml metaphosphate, 1 mg/ml hexametaphosphate, and 5 mM 15 
tetrapolyphosphate were 2.3, 1.9, and 0.5%, respectively, compared with NADK 16 
activity assayed in the presence of 5.0 mM ATP. 17 
 18 





Determining how human NADK is regulated by NADP
+
, NADPH, and NADH 21 
is a crucial step in understanding how human NADK influences the intracellular 22 
redox balance. Although NADP
+
 exhibited no inhibitory effect on NADK activity of 23 
human NADK, NADPH and NADH showed competitive inhibitions with Ki values 24 
13 
 
of 0.13 mM for NADPH and 0.34 mM for NADH (Table 4, Fig. 3, Online Resource 1 
Fig. S1). This agrees with a previous report, which shows that NADK activity of 2 
partially purified pigeon liver NADK is competitively inhibited by NADPH and 3 
NADH, while the effect of NADP
+
 on NADK activity of the enzyme was not 4 
investigated [29]. Although the information regarding the effect of these nucleotides 5 
on NADK activity has been limited, M. tuberculosis NADK has been reported to be 6 
inhibited by NADH, NADP
+
, and NADPH, wherein NADP
+
 is the most potent 7 
inhibitor [18]. The residual NADK activity of M. tuberculosis NADK was 22, 43, 8 
and 50% in the presence of 0.40 mM NADP
+
, NADPH, and NADH, respectively, 9 
although the inhibitory mechanism has not been investigated [18]. The fact that 10 
NADP
+
 inhibits M. tuberculosis NADK but not human NADK is a clue to design a 11 
novel antimicrobial drug, i.e., an analog of NADP
+
, which would possibly inhibit 12 
only M. tuberculosis NADK, thereby being lethal to the bacterium and not the host. 13 
Recently, Pollak et al. [27] established human cell lines overexpressing human 14 
NADK (NADK(+) cells). In NADK(+) cells that showed approximately 180-fold 15 
higher NADK activity than control cells, the NADPH level increased by 4- to 5-fold, 16 
and not 180-fold, while the NADP
+
 level was not prominently altered. The authors 17 
suggested that human NADK may be inhibited by NADPH. Our data demonstrating 18 
the inhibition of human NADK by NADPH convincingly support their suggestion. 19 
Taken together the low NADH kinase activity of human NADK, NADPH would be 20 
produced by NADP
+
-dependent dehydrogenases through reduction of NADP
+
. The 21 
fact that human NADK is localized in the cytosol [27] and that NADPH, but not 22 
NADP
+
, is significant for the regulation of human NADK would indicate that the 23 
function of cytosolic NADP
+





 synthesis (NADK activity), although the physiological role of 1 
inhibition of human NADK by NADH remains unclear.  2 
NADPH is required to protect cells against oxidative stress, and cytosolic 3 
NADP
+
-dependent glucose-6-phosphate dehydrogenase in human cells is induced 4 
when exposed to oxidative stress [30]. When cells survive against oxidative stress, 5 
intracellular NADPH is consumed and resynthesized quickly, while human NADK 6 
synthesizes NADP
+
 to guarantee the intracellular requirement for NADPH. When 7 
oxidative stress is removed, the abundant NADPH inhibits NADP
+
 synthesis to 8 
prevent accumulation of excess NADP
+
 and NADPH, thus resulting in the 9 
maintenance of homeostasis of intracellular NADP
+
 and NADPH. 10 
 11 
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Figure legends 1 
 2 
Fig. 1. SDS-PAGE of purified human NADK. (a) Purified human NADK (110 µg 3 
protein). (b) Purified human NADK obtained without heat treatment (60 µg protein). 4 
Arrowheads indicate the positions of the purified human NADK. 5 
 6 
Fig. 2. Kinetic analysis of human NADK. (a) The effect of substrate concentration 7 
([ATP] or [NAD
+
], mM) on the initial velocity (V, U/mg) of the reaction was assayed 8 
in the presence of 5 mM NAD
+
 and various concentrations of ATP (closed squares) 9 
or 5 mM ATP and various concentrations of NAD
+
 (open squares). Data represent the 10 
means of three measurements. (b) Hanes–Woolf plot of the data in (a). 11 
 12 
Fig. 3. Inhibitory effects of NADH (a, b) and NADPH (c, d) on human NADK. The 13 





], mM). (a) Saturation curve for NAD
+
 determined 15 
in the presence of 0 mM (closed squares), 0.3 mM (open circles), and 0.5 mM (closed 16 
circles) NADH. (b) Lineweaver–Burk plot of the data in (a). (c) Saturation curve for 17 
NAD
+
 determined in the presence of 0 mM (closed squares) and 0.5 mM (open 18 
squares) NADPH. (d) Lineweaver–Burk plot of the data in (c). 19 
 20 
Online Resource figure legend  21 
 22 
Online Resource Fig. S1. Inhibitory effects of NADH (a, b) and NADPH (c, d) on 23 
human NADK. (a) Hanes–Woolf plot of the data in Fig. 3a. (b) Eadie plot of the data 24 
20 
 
in Fig. 3a. The plot was determined in the presence of 0 mM (closed squares), 0.3 1 
mM (open circles), and 0.5 mM (closed circles) NADH. (c) Hanes–Woolf plot of the 2 
data in Fig. 3c. (d) Eadie plot of the data in Fig. 3c. The plot was determined in the 3 




















Expression of human NADK. 
Host cell Specific activity (U/mg)
a
 Relative activity (fold) 
M15 (pREP4) 0.23 1 
Rosetta-gami 1.02 4.4 
Rosetta-gami(DE3) 0.79 3.4 
Rosetta-gami(DE3)pLysS 4.29 18.7 
a








Improvement in the methods for expression and purification of human NADK. 
 Previous study [22] Present study 
Specific activity of 
expressed human NADK 








Purification procedure Three steps 
(Heat treatment and 





and TALON column 
chromatography) 







Specific activity of 
purified human NADK 
n.r.
a
 9.34 U/mg 








n.r.; not reported. 
b
The value obtained in this study (Table 1). 
c
Purified human NADK (15 mg) was obtained from a 13.5 l culture. 
d
N-terminal amino acid sequence of the purified human NADK was not determined 
in the previous report [22], while homogeneity of this enzyme was confirmed by 












Properties of human NADK. 
 Previous study [22] Present study 







Km (mM) for NAD
+
 0.54  1.07  
Km (mM) for ATP 3.3  - 
S0.5 (mM) for ATP - 3.6  
nH - 1.6 
Vmax (U/mg) for NAD
+
 6.7  18.5  
Vmax (U/mg) for ATP - 18.5 
Optimum temperature (°C) 55  50  











Table 4  
Inhibitory effects of NADP
+
, NADPH, and NADH on human NADK
a
. 
Compound Concentration (mM) Specific activity (U/mg)
b
 Relative activity (%) 
None 0 8.75  0.66 100 
NADP
+
 0.5 8.92  2.26 102 
NADPH 0.5 5.83  0.49 66 
NADPH 0.3 7.08  0.42 81 
NADH
c
 0.5 3.54  0.48 40 
NADH
c
 0.3 5.03  0.61 58 
NADH
c
 0.1 6.30  0.36 72 
a
NADK activity was assayed in the presence of 1.0 mM NAD
+
 and indicated compound. 
b
Means and standard deviations of three independent assays are indicated. 
c
Inhibitory effect of NADH was not attributed to NADH kinase activity of human 
NADK since the activity assayed in the presence of 0.3 or 0.5 mM NADH was only 10% 
of NADK activity assayed in the presence of 1.0 mM NAD
+
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